Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Have a pterygium in at least one eye that has not been previously removed with surgery

Exclusion Criteria:

• Uncontrolled systemic disease

• Active eye disease

• Current or anticipated use of topical eye medications other than artificial tears.

• Anticipated wearing of contact lenses